johnnyboy
the revenues were from contract services from Biophan-Europe (which does MRI testing, among other things) as well as the amortized licensing fee paid by BSX to Biophan, and also scientific consulting fees from Biomed related to the development work of Myotech, in which Biophan now owns a minority stake.
Notice the loss per quarter has been more than cut in half. Biophan is still a development stage company, and therefore the relentless screams for better revenues from 'some parties' seems to miss the point entirely. As soon as an MRI-safe and/or imageable implant product is launched by Boston Scientific, Biophan will advance to the commercialization stage of their growth, and cease to be called a development stage company. The comany is not there yet. Therefore it shouldn't be a big surprise that revenues are still low. They are, however, growing modestly.
Market Data 
Markets 
AI
